This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hernando, F. Articles by Burbach, J. P. H. Search for Related Content PubMed PubMed Citation Articles by Hernando, F. Articles by Burbach, J. P. H.

Immunohistochemical Localization of the Vasopressin V1b Receptor in the Rat Brain and Pituitary Gland: Anatomical Support for Its Involvement in the Central Effects of Vasopressin¹

Section of Molecular Science (F.H., O.S., J.P.H.B.), Department of Medical Pharmacology, Rudolf Magnus Institute for Neurosciences, University Medical Center, 3584 CG Utrecht, The Netherlands; and Department of Medicine (S.J.L.), University of Bristol, Bristol, BS2 8HW United Kingdom

Address all correspondence and requests for reprints to: J. P. H. Burbach, Rudolf Magnus Institute for Neurosciences, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands. E-mail: j.p.h.burbach{at}med.uu.nl

Biological effects of vasopressin (VP) are mediated by four different receptors, two of which (the V1a and the oxytocin receptors) have been well characterized in the rodent brain, suggesting that these are the main receptors responsible for the central effects of VP. However, transcripts of the V1b VP receptor (V1bR) have been detected throughout the rat brain by RT-PCR and in situ hybridization, indicating that the V1bR adds to the population of central VP receptors. Because there are no specific ligands for the V1bR, the receptor protein itself has been difficult to visualize. In the present study, the distribution of the V1bR protein was investigated in the rat forebrain, midbrain, hindbrain, and cerebellum by immunohistochemistry using an antiserum raised against a synthetic fragment of the carboxylterminal of the rat V1bR protein. Immunohistochemistry revealed the presence of the V1bR in pituitary corticotrophs as expected. In naive, untreated rats, fiber networks containing V1bR-immunoreactivity were mainly concentrated in the hypothalamus, amygdala, cerebellum, and particularly in those areas with a leaky blood brain barrier or close to the circumventricular organs (medial habenula, subfornical organ, organum vasculosum laminae terminalis, median eminence, and nuclei lining to the third and fourth ventricles). A strikingly dense network was present in the external zone of the median eminence. Colchicine treatment was required to reveal the localization of V1bR-immunoreactive cell bodies. V1bR-containing cell bodies and associated protrusions were mainly located in the hippocampus, caudate putamen, cortex, thalamus, olfactory bulb, and cerebellum. These results demonstrate the widespread distribution of the V1bR protein in the rat brain over multiple, functionally distinct neuronal systems. These data suggest that the V1bR mediates different physiological functions of VP in the brain.

This article has been cited by other articles:

				D. Zelena, K. Langnaese, A. Domokos, O. Pinter, R. Landgraf, G. B. Makara, and M. Engelmann Vasopressin Administration into the Paraventricular Nucleus Normalizes Plasma Oxytocin and Corticosterone Levels in Brattleboro Rats Endocrinology, June 1, 2009; 150(6): 2791 - 2798. [Abstract] [Full Text] [PDF]

				H. Orcel, L. Albizu, S. Perkovska, T. Durroux, C. Mendre, H. Ansanay, B. Mouillac, and A. Rabie Differential Coupling of the Vasopressin V1b Receptor through Compartmentalization within the Plasma Membrane Mol. Pharmacol., March 1, 2009; 75(3): 637 - 647. [Abstract] [Full Text] [PDF]

				K. Nakamura, Y. Fujiwara, R. Mizutani, A. Sanbe, N. Miyauchi, M. Hiroyama, J. Yamauchi, T. Yamashita, S. Nakamura, T. Mori, et al. Effects of Vasopressin V1b Receptor Deficiency on Adrenocorticotropin Release from Anterior Pituitary Cells in Response to Oxytocin Stimulation Endocrinology, October 1, 2008; 149(10): 4883 - 4891. [Abstract] [Full Text] [PDF]

				R. Arban V1b Receptors: New Probes for Therapy Endocrinology, September 1, 2007; 148(9): 4133 - 4135. [Full Text] [PDF]

				A. Pena, B. Murat, M. Trueba, M. A. Ventura, G. Bertrand, L. L. Cheng, S. Stoev, H. H. Szeto, N. Wo, G. Brossard, et al. Pharmacological and Physiological Characterization of d[Leu4, Lys8]Vasopressin, the First V1b-Selective Agonist for Rat Vasopressin/Oxytocin Receptors Endocrinology, September 1, 2007; 148(9): 4136 - 4146. [Abstract] [Full Text] [PDF]

				Y. Fujiwara, M. Hiroyama, A. Sanbe, J. Yamauchi, G. Tsujimoto, and A. Tanoue Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice J. Endocrinol., February 1, 2007; 192(2): 361 - 369. [Abstract] [Full Text] [PDF]

				S. Milutinovic, D. Murphy, and N. Japundzic-Zigon The role of central vasopressin receptors in the modulation of autonomic cardiovascular controls: a spectral analysis study Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1579 - R1591. [Abstract] [Full Text] [PDF]

				S. Itoh, S. Yamada, T. Mori, T. Miwa, K. Tottori, Y. Uwahodo, Y. Yamamura, M. Fukuda, K. Yamamoto, A. Tanoue, et al. Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E147 - E151. [Abstract] [Full Text] [PDF]

				J. ANTUNES-RODRIGUES, M. DE CASTRO, L. L. K. ELIAS, M. M. VALENCA, and S. M. McCANN Neuroendocrine Control of Body Fluid Metabolism Physiol Rev, January 1, 2004; 84(1): 169 - 208. [Abstract] [Full Text] [PDF]

				S. Derick, L. L. Cheng, M. J. Voirol, S. Stoev, M. Giacomini, N. C. Wo, H. H. Szeto, M. Ben Mimoun, M. Andres, R. C. Gaillard, et al. [1-Deamino-4-Cyclohexylalanine] Arginine Vasopressin: A Potent and Specific Agonist for Vasopressin V1b Receptors Endocrinology, December 1, 2002; 143(12): 4655 - 4664. [Abstract] [Full Text] [PDF]

				C. S.-L. Gal, J. Wagnon, J. Simiand, G. Griebel, C. Lacour, G. Guillon, C. Barberis, G. Brossard, P. Soubrie, D. Nisato, et al. Characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1122 - 1130. [Abstract] [Full Text] [PDF]

				A. Hurbin, H. Orcel, G. Alonso, F. Moos, and A. Rabie The Vasopressin Receptors Colocalize with Vasopressin in the Magnocellular Neurons of the Rat Supraoptic Nucleus and Are Modulated by Water Balance Endocrinology, February 1, 2002; 143(2): 456 - 466. [Abstract] [Full Text] [PDF]